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Abstract
Background: Recently, Plasmodium falciparum parasites bearing Pfdhfr I164L single mutation were found in
Madagascar. These new mutants may challenge the use of antifolates for the intermittent preventive treatment of
malaria during pregnancy (IPTp). Assays with transgenic bacteria suggested that I164L parasites have a wild-type
phenotype for pyrimethamine but it had to be confirmed by testing the parasites themselves.
Methods: Thirty Plasmodium falciparum clinical isolates were collected in 2008 in the south-east of Madagascar. A
part of Pfdhfr gene encompassing codons 6 to 206 was amplified by PCR and the determination of the presence
of single nucleotide polymorphisms was performed by DNA sequencing. The multiplicity of infection was
estimated by using an allelic family-specific nested PCR. Isolates that appeared monoclonal were submitted to
culture adaptation. Determination of IC50s to pyrimethamine was performed on adapted isolates.
Results: Four different Pfdhfr alleles were found: the 164L single mutant-type (N = 13), the wild-type (N = 7), the
triple mutant-type 51I/59R/108N (N = 9) and the double mutant-type 108N/164L (N = 1). Eleven out 30 (36.7%) of
P. falciparum isolates were considered as monoclonal infection. Among them, five isolates were successfully
adapted in culture and tested for pyrimethamine in vitro susceptibility. The wild-type allele was the most
susceptible with a 50% inhibitory concentration (IC50) < 10 nM. The geometric mean of IC50 of the three I164L
mutant isolates was 6-fold higher than the wild-type with 61.3 nM (SD = 3.2 nM, CI95%: 53.9-69.7 nM). These
values remained largely below the IC50 of the triple mutant parasite (13,804 nM).
Conclusion: The IC50s of the I164L mutant isolates were significantly higher than those of the wild-type (6-fold
higher) and close from those usually reported for simple mutants S108N (roughly10-fold higher than wild type).
Given the observed values, the determination of IC50s directly on parasites did not confirm what has been found
on transgenic bacteria. The prevalence increase of the Pfdhfr I164L single mutant parasite since 2006 could be
explained by the selective advantage of this allele under sulphadoxine-pyrimethamine pressure. The emergence of
highly resistant alleles should be considered in the future, in particular because an unexpected double mutant-type
allele S108N/I164L has been already detected.
Background
Plasmodium falciparum malaria remains a major cause
of morbidity and mortality in endemic areas, affecting
mainly African children under five years of age and
pregnant women [1]. Currently, in these areas, artemisi-
nin combinations therapy (ACT) is recommended as
first-line treatment for uncomplicated P. falciparum
malaria, while the intermittent preventive treatment of
malaria in pregnancy (IPTp) relies on the administration
of antifolate sulphadoxine-pyrimethamine (SP) combina-
tion. Anti-malarial drugs used for IPTp must be effica-
cious, safe, tolerable, cheap, and easy to administer,
preferably as a single dose [2]. So far, SP is the only
drug which has these attributes, despite its decreasing
efficiency [3].
Analysis of the molecular basis of anti-malarial drug
resistance has demonstrated that mutations in the dihy-
drofolate reductase (dhfr) and dihydropteroate synthase
genes are associated with development of SP resistance.
Resistance to pyrimethamine (PYR) is due to point
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gene (Pfdhfr) [4-9] and the PfDHFR S108N point muta-
tion is the main molecular event, followed by stepwise
selection of additional mutations in other positions
(codons 51, 59 and 164). Several studies have already
demonstrated that parasites with a triple-mutant allele
(N51I/C59R/S108N) have markedly reduced in vitro sus-
ceptibility to PYR, and the presence of the triple-muta-
tion allele increases the risk of SP therapeutic failure
[10]. An additional mutation, I164L, confers to the
quadruple mutant a high level of resistance to PYR [11],
abrogating the clinical efficacy of SP as observed in
Southeast Asia and South America [12] but rarely in
Africa [13].
In African countries and the Comoros Island, three
haplotypes including the I164L allele have been
described: both triple mutants N51I/S108N/I164L and
C59R/S108N/I164L, and the quadruple mutant [14,15].
In 2006, a novel I164L single mutant in one field isolate
in Madagascar was observed [16]. In 2008, the Pfdhfr
I164L polymorphism was prevalent in southern sentinel
sites of the Great Island with 8.8% of isolates carrying
this mutation [14]. Microsatellite markers analysis
showed that this unique allele emerged independently in
these sites. Until now, the Pfdhfr I164L allele has not
been reported elsewhere in the world. Previous pub-
lished data have also shown that the triple mutant
N51I/C59R/S108N have largely spread in Madagascar
but the quadruple mutant has not been reported so far.
In 2009, Lozovsky et al have explored and analysed
t h ep o s s i b l ee v o l u t i o n a r yp a t h w a y so fP Y Rr e s i s t a n c e
using experimental systems with transgenic bacteria in
which all possible mutational intermediates were created
by site-directed mutagenesis (N51I, C59R, S108N, and
I164L) in PfDHFR enzyme [17]. Their findings suggested
that P. falciparum parasites harbouring single mutant
Pfdhfr I164L (IC50 =0 . 2 9μg/ml) were as sensitive to
PYR as the wild type allele (0.27 μg/ml). This data was
not consistent with the observation of the rapid rise in
t h ep r e v a l e n c eo fp a r a s i t e sw i t ht h es i n g l e1 6 4 Lm u t a -
tion in Madagascar following the massive use of the SP
[14].
In this context, the main objective of the study was to
assess the PYR in vitro susceptibility of parasites them-
selves and to compare those harboring the single 164L
mutation with those harbouring wild-type and triple-
mutant Pfdhfr alleles in order to decipher the epidemio-
logical characteristics of this haplotype.
Methods
Sample collection
Plasmodium falciparum clinical isolates were collected
in 2008 from patients seeking treatment for malaria at
Farafangana Health Centre in the south-east of
Madagascar where high prevalence of Pfdhfr I164L sin-
gle mutant allele was previously observed [18]. All
patients with fever were screened with the CareStart
©
r a p i dd i a g n o s t i ct e s t( A c c e s s B i o
©). Giemsa-stained thin
and thick blood films were prepared for each patient
with a positive rapid diagnostic test result. The various
species of Plasmodium were identified and parasitaemia
was assessed by a skilled microscopist. Once informed
consent had been obtained from all adults and from at
least one parent for minors, 5 ml of venous blood were
collected on EDTA tube. Patients with positive micro-
scopy results were promptly treated according to
National Malaria Policy. Blood samples were sent to
Institut Pasteur, Antananarivo, at +4°C within 24 to 48
h of collection. Giemsa-stained thin blood smears were
examined to check for mono-infection with P. falci-
parum and to determine parasite density. Plasmodium
falciparum samples were split into two different ali-
quots: cryopreserved aliquots stored in liquid nitrogen
for culture adaptation and in vitro assays, and fresh
blood aliquots stored at -20°C until genomic DNA
extraction.
Genomic DNA extraction
DNA was extracted from initial infected blood aliquots
and from parasites obtained after culture adaptation, by
the phenol-chloroform method [19].
Plasmodium species molecular diagnosis
Parasite species were confirmed in both DNA extracts
by real-time PCR, using species-specific primers as
described by de Monbrison [20] with a protocol adapted
for the RotorGene
® 3000 thermocycler (Corbett Life
Science
®, Sydney, Australia).
Pfdhfr amplification & sequencing
A 600 bp fragment of Pfdhfr gene encompassing codons
6 to 206 was amplified by nested PCR technique on
both DNA extracts, as previously described [21].
Sequencing reactions were carried out with a ABI Prism
BigDye Terminator cycle sequencing ready reaction kit
and were run on a model 3730 xl genetic analyzer
(Applied Biosystems, Courtaboeuf, France). Electrophor-
egrams were visualized and analyzed with CEQ2000
genetic analysis system software (Beckman Coulter, Vil-
lepinte, France). The amino acid sequences were com-
pared with the 3D7 PfDHFR wild-type amino acid
sequence (PFD0830w, GenBank accession number
AL844503). The presence of single nucleotide poly-
morphisms was confirmed by reading both the forward
and the reverse strands. Parasites with mixed alleles (in
which both wild-type and mutant alleles were present)
were considered mutants. Haplotypes for drug resistance
markers were reconstructed from the full sequence
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positions.
Multiplicity of infection (MOI)
The multiplicity of infection, defined as the highest
number of alleles detected at either of the two loci, was
estimated by using an allelic family-specific nested PCR
(MAD20, K1, and RO33 for Pfmsp-1 and 3D7 and FC27
for Pfmsp-2), as described previously (1). All PCR ampli-
fications of initial infected blood aliquots contained a
positive control (genomic DNA from strains W2, HB3,
and 3D7) and a negative control (no target DNA). Only
samples showing monoclonal P. falciparum infections
were selected for culture adaptation.
Culture adaptation and in vitro susceptibility assays
Aliquots preserved in liquid nitrogen were sent to IRBA,
Marseille, France, for culture adaptation and assessment
of 50% inhibitory concentration (IC50) to PYR. PYR was
o b t a i n e df r o mS i g m a( S t .L o u i s ,M O ) .S t o c ks o l u t i o n
was prepared in ethanol. Twofold serial dilutions were
prepared in sterile water and distributed in triplicate
into Falcon 96-well flat-bottomed plates (Becton Dickin-
son, Franklin Lakes, NJ). The 3D7 clone (wild-type
Pfdhfr allele) and the W2 Indochina clone (triple
mutant-type Pfdhfr allele) were obtained from MR4-
ATCC (Manassas, VA, USA) and used as controls to
test the batch of plates.
Determination of the in vitro susceptibility was per-
formed in triplicate on culture adapted isolates and on
references strains, using the in vitro isotopic microtest
as previously described [22]. The 50% inhibitory concen-
tration (IC50), i.e., the drug concentration corresponding
to 50% of the uptake of [
3H] hypoxanthine by the para-
sites in drug-free control wells, was determined by non-
linear regression analysis of log dose-response curves
(Riasmart; Packard, Meriden, NJ). Data were analysed
after logarithmic transformation and expressed as the
geometric mean IC50, and 95% confidence intervals were
calculated (Stata 9; StataCorp LP, Texas, USA).
Ethical approval
The study protocol was reviewed and approved by the
Ethics Committee of the Ministry of Health of Madagas-
car (N°007/SANPF/2007). An informed written consent
was provided by the parents/guardians of all patients
before they were included in the study.
Results
Thirty P. falciparum samples were collected in a four-
day mission with parasitaemia ranging from 0.01 to
0.72%. Among them, sequencing of the Pfdhfr gene
revealed four different alleles: the 164L single mutant-
type (N = 13), the wild-type (N = 7), the triple mutant-
type 51I/59R/108N (N = 9) and the double mutant-type
108N/164L (N = 1). The latter allele was observed for
the first time in this area.
Genotyping of collected isolates showed that 11/30
(36.7%) of P. falciparum isolates had a single allelic
form and were considered as monoclonal infection:
164L single mutant-type allele (4/13), wild-type allele (2/
7), triple mutant-type 51I/59R/108N allele (4/9) and
double mutant-type allele 108N/164L (1/1). Among
them, five isolates were successfully adapted in culture
(1 isolate with wild-type allele, three isolates with 164L
single mutant-type allele and one isolate with triple
mutant-type 51I/59R/108N allele) and tested for PYR in
vitro susceptibility. On these samples, Pfdhfr genotypes
and MOI which were assessed after the culture adapta-
tion period were identical to initial samples.
Pyrimethamine IC50s were significantly different
among the three Pfdhfr alleles (P < 0.001). The wild-
type allele was the most susceptible with an IC50 <1 0
nM. The geometric mean of IC50 of the three I164L
mutant isolates was significantly higher (6-fold, P <
0.001) than the wild-type with 61.3 nM (SD = 3.2 nM,
CI95%: 53.9-69.7 nM). These values remained largely
below the IC50 o ft h et r i p l em u t a n tp a r a s i t et e s t e di n
the assay which was 13,804 nM.
Discussion & Conclusion
The main result of this study was that I164L mutant
isolates did not show fully susceptible IC50s, but values
that were significantly higher than those of the wild-
type (six-fold higher). These values were nearer to what
is usually reported for simple mutants S108N
(roughly10-fold higher than wild type) [23]. Thus, the
determination of IC50s directly on parasites did not con-
firm on that specific point what has been found by
Lozowski et al using transgenic bacteria. The adaptation
of isolates to culture conditions is a delicate process,
which is not always successful. In the present study,
three clonal infections by parasites harbouring the I164L
mutations were adapted, which enabled us to observe
the low SD of the IC50s to PYR between these strains.
Given the observed values of IC50s, the presence of
Pfdhfr I164L single mutant parasites did not challenge
the current use of SP for IPTp in Madagascar. Indeed,
I164L mutant isolates could not been considered as
resistant because the usual threshold for PYR resistance
was defined as > 2,000 nM, the intermediate values,
100-2000 nM, representing moderate resistance [24].
However, the emergence of highly resistant alleles
should be considered as possible for two reasons: first,
the prevalence of the I164L allele has increased since
year 2006 (14 isolates out 30 (46.7%) in the present ser-
ies) and second, the presence of the double mutant-type
allele S108N/I164L has been detected in a monoclonal
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has been formed either on a background of S108N or
I164L. This pathway was not expected according to the
model of Lozovsky et al,b u to b v i o u s l yi to c c u r r e di n
the real life. As I164L simple mutant genotype is not
found today in another area in the world, Malagasy
parasites may have a particular background, which
enabled the emergence of this double mutant genotype.
A highly resistant IC50 (103 μg/ml) for the S108N/I164L
genotype was found using transgenic bacteria [17].
Unfortunately, the S108N/I164L isolate was not success-
fully adapted to culture and it was consequently impos-
sible to confirm this in vitro resistance level.
Interestingly, these authors reported that the low fitness
of the quadruple mutant in the absence of PYR was not
observed in transgenic bacteria having the S108N/I164L
genotype. If these characteristics were to apply to nat-
ural parasites, it could have implications in terms of
transmission of these strains. The triple mutant-type
51I/59R/108N was also largely prevalent (9 out 30 (30%)
isolates) in the area and may represent a possible back-
ground for the emergence of the quadruple mutant. In
addition, the diffusion of the quadruple mutant from the
Comoros Islands remains possible and could be a source
of highly resistant parasites. Combinations of DHFR and
DHPS inhibitors act synergistically. To further docu-
ment the impact of the Pfdhfr I164L mutation in SP
resistance it may be interesting to determine poly-
morphisms in Pfdhps gene, which was not done for iso-
lates of the present series. A previous work performed
in a large series in 2007 in Madagascar showed that 46%
of isolates harboured the Pfdhps A437G mutation [14].
For all these reasons, epidemiological surveillance is
needed in the future to monitor the use of SP in IPTp.
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